Releases Details

MaxCyte, Inc.

("MaxCyte" or the "Company")

Issue of Equity from exercise of Share Options

Maryland, USA -03 January 2017: MaxCyte (LSE: MXCT) announces the issue and allotment of 18,293 new shares of common stock of $0.01 each in the Company (the "New Common Stock") pursuant to the exercise of share options by a certain option holder.

Application has been made for the New Common Stock to be admitted to trading on AIM ("Admission") and it is expected that Admission will take place at 8.00 a.m. on or around 9 January 2017. The New Common Stock will rank pari passu with the existing shares  of common stock of the Company. Following this allotment and Admission, the total issued stock capital of the Company will increase to 43,539,527 shares of common stock. Shareholders in the Company may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the stock capital of the Company.

- ENDS -

For further information please contact:

About MaxCyte

MaxCyte is an established and revenue generating US-based developer and supplier of cell engineering products and services to biopharmaceutical firms engaged in cell therapy, drug discovery and development, biomanufacturing, gene editing and immuno-oncology markets, which independent market analyses estimate to be, in aggregate, in excess of $35 billion in 2015. The Company's patented flow electroporation technology enables its products to deliver fast, reliable and scalable cell engineering to drive the research and clinical development of a new generation of medicines.

MaxCyte's high performance platform allows transfection with any molecule or multiple molecules and is compatible with nearly all cell types, including hard-to-transfect human primary cells. It also provides a high degree of consistency and minimal cell disturbance, thereby facilitating rapid, large scale, clinical and commercial grade cell engineering in a non-viral system and with low toxicity concerns. The Company's cell engineering technology platform is CE-marked and FDA-accredited, providing MaxCyte's customers and partners with an established regulatory path.

Using the unique capabilities of its technology, MaxCyte is developing CARMA, its proprietary platform in immuno-oncology, to deliver a validated non-viral approach to CAR therapies across a broad range of cancer indications, including solid tumors where existing CAR-T approaches face significant challenges.

For more information visit http://www.maxcyte.com/